95 related articles for article (PubMed ID: 20130232)
1. Genetic association of the CCR5 region with lipid levels in at-risk cardiovascular patients.
Hyde CL; Macinnes A; Sanders FA; Thompson JF; Mazzarella RA; Faergeman O; van Wijk DF; Wood L; Lira M; Paciga SA
Circ Cardiovasc Genet; 2010 Apr; 3(2):162-8. PubMed ID: 20130232
[TBL] [Abstract][Full Text] [Related]
2. Influence of SCARB1 polymorphisms on serum lipids of hypercholesterolemic individuals treated with atorvastatin.
Cerda A; Genvigir FD; Arazi SS; Hirata MH; Dorea EL; Bernik MM; Bertolami MC; Faludi AA; Hirata RD
Clin Chim Acta; 2010 May; 411(9-10):631-7. PubMed ID: 20064494
[TBL] [Abstract][Full Text] [Related]
3. Comparison of rosuvastatin with atorvastatin, simvastatin and pravastatin in achieving cholesterol goals and improving plasma lipids in hypercholesterolaemic patients with or without the metabolic syndrome in the MERCURY I trial.
Stender S; Schuster H; Barter P; Watkins C; Kallend D;
Diabetes Obes Metab; 2005 Jul; 7(4):430-8. PubMed ID: 15955130
[TBL] [Abstract][Full Text] [Related]
4. Long-term (18-month) efficacy of atorvastatin therapy in type 2 diabetics at cardiovascular risk.
Velussi M
Nutr Metab Cardiovasc Dis; 2002 Feb; 12(1):29-35. PubMed ID: 12125227
[TBL] [Abstract][Full Text] [Related]
5. Beneficial effects of atorvastatin on sd LDL and LDL phenotype B in statin-naive patients and patients previously treated with simvastatin or pravastatin.
Baldassarre S; Scruel O; Deckelbaum RJ; Dupont IE; Ducobu J; Carpentier YA
Int J Cardiol; 2005 Oct; 104(3):338-45. PubMed ID: 16186066
[TBL] [Abstract][Full Text] [Related]
6. Adiponectin plasma levels are increased by atorvastatin treatment in subjects at high cardiovascular risk.
Blanco-Colio LM; Martín-Ventura JL; Gómez-Guerrero C; Masramon X; de Teresa E; Farsang C; Gaw A; Gensini G; Leiter LA; Langer A; Egido J
Eur J Pharmacol; 2008 May; 586(1-3):259-65. PubMed ID: 18374327
[TBL] [Abstract][Full Text] [Related]
7. Genetic variation in the hepatic lipase gene is associated with combined hyperlipidemia, plasma lipid concentrations, and lipid-lowering drug response.
Cenarro A; Artieda M; Gonzalvo C; Meriño-Ibarra E; Arístegui R; Gañán A; Díaz C; Sol JM; Pocoví M; Civeira F;
Am Heart J; 2005 Dec; 150(6):1154-62. PubMed ID: 16338252
[TBL] [Abstract][Full Text] [Related]
8. Associations of chemokine system polymorphisms with clinical outcomes and treatment responses of chronic hepatitis C.
Promrat K; McDermott DH; Gonzalez CM; Kleiner DE; Koziol DE; Lessie M; Merrell M; Soza A; Heller T; Ghany M; Park Y; Alter HJ; Hoofnagle JH; Murphy PM; Liang TJ
Gastroenterology; 2003 Feb; 124(2):352-60. PubMed ID: 12557141
[TBL] [Abstract][Full Text] [Related]
9. Elevated ICAM-1 and MCP-1 plasma levels in subjects at high cardiovascular risk are diminished by atorvastatin treatment. Atorvastatin on Inflammatory Markers study: a substudy of Achieve Cholesterol Targets Fast with Atorvastatin Stratified Titration.
Blanco-Colio LM; Martín-Ventura JL; de Teresa E; Farsang C; Gaw A; Gensini G; Leiter LA; Langer A; Martineau P; Egido J;
Am Heart J; 2007 May; 153(5):881-8. PubMed ID: 17452168
[TBL] [Abstract][Full Text] [Related]
10. LDL-C/HDL-C ratio in subjects with cardiovascular disease and a low HDL-C: results of the RADAR (Rosuvastatin and Atorvastatin in different Dosages And Reverse cholesterol transport) study.
Jukema JW; Liem AH; Dunselman PH; van der Sloot JA; Lok DJ; Zwinderman AH
Curr Med Res Opin; 2005 Nov; 21(11):1865-74. PubMed ID: 16307708
[TBL] [Abstract][Full Text] [Related]
11. Effects of rosuvastatin versus atorvastatin, simvastatin, and pravastatin on non-high-density lipoprotein cholesterol, apolipoproteins, and lipid ratios in patients with hypercholesterolemia: additional results from the STELLAR trial.
Jones PH; Hunninghake DB; Ferdinand KC; Stein EA; Gold A; Caplan RJ; Blasetto JW;
Clin Ther; 2004 Sep; 26(9):1388-99. PubMed ID: 15531001
[TBL] [Abstract][Full Text] [Related]
12. Physical activity modulates the combined effect of a common variant of the lipoprotein lipase gene and smoking on serum triglyceride levels and high-density lipoprotein cholesterol in men.
Sentí M; Elosua R; Tomás M; Sala J; Masiá R; Ordovás JM; Shen H; Marrugat J
Hum Genet; 2001 Oct; 109(4):385-92. PubMed ID: 11702219
[TBL] [Abstract][Full Text] [Related]
13. Plasma triglycerides and cardiovascular events in the Treating to New Targets and Incremental Decrease in End-Points through Aggressive Lipid Lowering trials of statins in patients with coronary artery disease.
Faergeman O; Holme I; Fayyad R; Bhatia S; Grundy SM; Kastelein JJ; LaRosa JC; Larsen ML; Lindahl C; Olsson AG; Tikkanen MJ; Waters DD; Pedersen TR;
Am J Cardiol; 2009 Aug; 104(4):459-63. PubMed ID: 19660594
[TBL] [Abstract][Full Text] [Related]
14. Achieving lipoprotein goals in patients at high risk with severe hypercholesterolemia: efficacy and safety of ezetimibe co-administered with atorvastatin.
Stein E; Stender S; Mata P; Sager P; Ponsonnet D; Melani L; Lipka L; Suresh R; Maccubbin D; Veltri E;
Am Heart J; 2004 Sep; 148(3):447-55. PubMed ID: 15389231
[TBL] [Abstract][Full Text] [Related]
15. Low high-density lipoprotein cholesterol and cardiovascular disease: risk reduction with statin therapy.
Rosenson RS
Am Heart J; 2006 Mar; 151(3):556-63. PubMed ID: 16504615
[TBL] [Abstract][Full Text] [Related]
16. A 52-week, randomized, open-label, parallel-group comparison of the tolerability and effects of pitavastatin and atorvastatin on high-density lipoprotein cholesterol levels and glucose metabolism in Japanese patients with elevated levels of low-density lipoprotein cholesterol and glucose intolerance.
Sasaki J; Ikeda Y; Kuribayashi T; Kajiwara K; Biro S; Yamamoto K; Ageta M; Kobori S; Saikawa T; Otonari T; Kono S
Clin Ther; 2008 Jun; 30(6):1089-101. PubMed ID: 18640465
[TBL] [Abstract][Full Text] [Related]
17. Effects of switching statins on achievement of lipid goals: Measuring Effective Reductions in Cholesterol Using Rosuvastatin Therapy (MERCURY I) study.
Schuster H; Barter PJ; Stender S; Cheung RC; Bonnet J; Morrell JM; Watkins C; Kallend D; Raza A;
Am Heart J; 2004 Apr; 147(4):705-13. PubMed ID: 15077101
[TBL] [Abstract][Full Text] [Related]
18. Lack of association between the chemokine receptor 5 polymorphism CCR5delta32 in rheumatoid arthritis and juvenile idiopathic arthritis.
Lindner E; Nordang GB; Melum E; Flatø B; Selvaag AM; Thorsby E; Kvien TK; Førre OT; Lie BA
BMC Med Genet; 2007 Jun; 8():33. PubMed ID: 17565662
[TBL] [Abstract][Full Text] [Related]
19. Effect of lowering LDL cholesterol substantially below currently recommended levels in patients with coronary heart disease and diabetes: the Treating to New Targets (TNT) study.
Shepherd J; Barter P; Carmena R; Deedwania P; Fruchart JC; Haffner S; Hsia J; Breazna A; LaRosa J; Grundy S; Waters D
Diabetes Care; 2006 Jun; 29(6):1220-6. PubMed ID: 16731999
[TBL] [Abstract][Full Text] [Related]
20. CCR2-64I polymorphism and CCR5Delta32 deletion in patients with Alzheimer's disease.
Galimberti D; Fenoglio C; Lovati C; Gatti A; Guidi I; Venturelli E; Cutter GR; Mariani C; Forloni G; Pettenati C; Baron P; Conti G; Bresolin N; Scarpini E
J Neurol Sci; 2004 Oct; 225(1-2):79-83. PubMed ID: 15465089
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
